

Antwerpen (BE), 16 maart 2022, 8:00 AM CET (embargo)

Precirix haalt 80 miljoen EUR op in Serie B. Gimv ondersteunt de verdere ontwikkeling van radiofarmaceutica

Brussel, België, 16 maart 2022 - Precirix NV, een klinisch biotechnologiebedrijf dat innovatieve radiofarmaceutica ontwikkelt in de oncologie, kondigt vandaag een Serie B-financieringsronde van 80 miljoen EUR aan, geleid door nieuwe investeerder INKEF Capital, samen met Jeito Capital en Forbion Capital Partners. De bestaande aandeelhouders van het bedrijf, Gimv, HealthCap, Novo Holdings, Pontifax Venture Capital, V-Bio Ventures, BioMed Partners, evenals de seed-investeerders, blijven het bedrijf steunen en namen deel aan de ronde.

De opbrengst van deze financieringsronde zal de ontwikkeling en uitbreiding van Precirix' pijplijn financieren. Meer specifiek zal het bedrijf CAM-H2 door haar lopende Fase I/II studie verderzetten en is het van plan om aanvullende nieuwe radiofarmaceutica naar de kliniek te brengen.

Michaël Vlemmix, Principal in het Health & Care-platform van Gimv en lid van Precirix' Raad van Bestuur, geeft aan: *"Precirix heeft aanzienlijke vooruitgang geboekt sinds haar Series A in 2018. De bijkomende financiering zal ons toelaten om het radiofarmaceutisch platform verder uit te bouwen, de pijplijn verder te diversifiëren en de klinische ontwikkelingen verder te zetten met als kerndoel om nieuwe geneesmiddelen naar patiënten te brengen. Gesteund door enkele van de sterkste namen in onze industrie, heeft het bedrijf een solide basis om verder te bouwen aan het verhaal naar succes."*

Voor meer informatie, gelieve in bijlage het volledige persbericht van Precirix te lezen.

OVER GIMV

Gimv is een Europese investeringsmaatschappij, genoteerd op Euronext Brussel. Met 40 jaar ervaring in private equity, heeft Gimv vandaag 2 miljard EUR onder beheer, met een portefeuille van ongeveer 55 bedrijven die samen een omzet van 2,8 miljard EUR realiseren en 15 000 professionals tewerkstellen..

Als erkend marktleider in geselecteerde investeringsplatformen identificeert Gimv ondernemende en innoverende bedrijven met een groot groeipotentieel en begeleidt ze in hun transformatie tot marktleiders. De vier investeringsplatformen zijn: Consumer, Health & Care, Smart Industries en Sustainable Cities. Elk van deze platformen werkt met een ervaren team in de thuismarkten van Gimv (Benelux, Frankrijk en DACH) en kan rekenen op een uitgebreid internationaal netwerk van deskundigen.

Meer informatie over Gimv vindt u op www.gimv.com.

Voor meer informatie, gelieve contact op te nemen met:

Michaël Vlemmix, Principal

T +32 3 290 21 77 – michael.vlemmix@gimv.com

Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals

Brussels, Belgium, 16 March 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads.

“We are delighted to announce this major milestone and are grateful for the strong investor support. The addition of Inkef, Jeito and Forbion, three leading VC funds in the healthcare sector, significantly reinforces our international shareholder base”, said Ruth Devenyns, CEO of Precirix. “The investment will allow Precirix to accelerate its growth trajectory and to further validate and broaden the technology platform.”

Precirix's platform brings together several unique features and facilitates the development of radiolabelled single-domain antibodies (sdAbs) for multiple targets, in combination with different isotopes and applicability in various settings. The company's lead product candidate, CAM-H2, is currently in a Phase I/II study for the treatment of HER2-positive metastatic breast and gastric cancer. The study allows inclusion of patients with brain metastases, a population in urgent need of effective therapies. Initial imaging data provide confidence in the potential of CAM-H2 to address the unmet medical need in this population. Patients are now being enrolled in the second cohort of the dose-escalation phase, following the absence of any dose-limiting toxicities in the first cohort and a positive review from the Safety Review Committee.

The proceeds of this financing round will fund the development and expansion of Precirix's pipeline. More specifically, the company will advance CAM-H2 through its ongoing Phase I/II study, and plans to bring additional novel radiopharmaceuticals to the clinic. Precirix will also focus on further strengthening the platform, using its potential to generate new product candidates, linkers and CMC processes.

Simone Botti, Partner at INKEF Capital, Sabine Dandiguian, Managing Partner at Jeito and Jasper Bos, General Partner at Forbion Growth will join Precirix's Board of Directors.

16 March 2022

Simone Botti, Partner at INKEF Capital said, *“Radiopharmaceuticals are showing great promise as therapies for difficult-to-treat cancers. Precirix’s innovative platform based on sdAb carriers has potential to truly improve clinical outcomes for patients. We are excited to support Precirix on its continued progress advancing first in class targeted radiopharmaceuticals towards commercialization.”*

Sabine Dandiguian, Managing Partner at Jeito Capital said, *“We are thrilled to co-lead this round with the ambition to support Precirix in bringing a breakthrough new alternative to patients suffering from advanced cancer, in total coherence with Jeito’s mission: ‘Go faster for the patient, further with the entrepreneur’.”*

Jasper Bos, General Partner at Forbion, working in the company’s Growth Fund noted, *“Forbion Growth was launched with the aim to build a portfolio of 10-12 investments in the most promising European late-stage life sciences companies. Precirix exemplifies the type of company we invest within the fund. I am confident of our ability to enable the team to build and transform patients’ lives.”*

The company’s existing shareholders Gimv, HealthCap, Novo Holdings, Pontifax Venture Capital, V-Bio Ventures, BioMed Partners, as well as the seed investors, continue to support the company having all participated in the round

ENDS

About Precirix NV

Precirix is a private, clinical-stage biopharmaceutical company founded in 2014 as a spin-off from the VUB, dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labelled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’s technology also allows for a theragnostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a therapeutic dose for treatment.

About INKEF Capital

INKEF Capital is a leading venture capital firm based in Amsterdam with a proven history in backing promising early stage companies in Europe. INKEF takes pride in being a patient, long-term investor with the ability to support companies through several funding rounds all the way up to IPO. From the early stages of being a technology or life science venture, INKEF supports entrepreneurs building their ideas into successful international businesses. INKEF’s investments include Onward Medical, Castor, iOnctura, Cardior and GitLAB, Remote among others.

16 March 2022

About Jeito Capital

Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access in Europe & the United States. Jeito Capital has EUR 534m under management. Jeito Capital is based in Paris with a presence in Europe and the United States.

About Forbion

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages well over EUR 1.8 billion across multiple fund strategies that cover all stages of (bio)pharmaceutical drug development. Forbion's current team consists of over 20 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in over 79 companies. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients.

For further information, please contact:

Ruth Devenyns, CEO

+32 2 479 93 60

info@precirix.comwww.precirix.comOptimum Strategic Communications

Mary Clark, Manel Mateus, Vici Rabbetts

Tel: +44 (0) 208 078 4357

Precirix@optimumcomms.com